These results might be due to dasatinib- and radotinib-induced c-KIT suppression by lysosomal processing (Cbl induction), and activation of the apoptotic pathway in c-KIT-positive AML cells (PARP and caspase activation; Supplementary Fig. 2 and Fig. 3). This evidence concerns the gene KIT and acute myeloid leukemia.